anti-c Abl phospho (Tyr412) antibody
ARG20573
ApplicationsWestern Blot
Product group Antibodies
ReactivityHuman, Mouse, Rat
TargetABL1
Overview
- SupplierArigo Biolaboratories
- Product Nameanti-c Abl phospho (Tyr412) antibody
- Delivery Days Customer23
- ApplicationsWestern Blot
- CertificationResearch Use Only
- ClonalityPolyclonal
- ConjugateUnconjugated
- Gene ID25
- Target nameABL1
- Target descriptionABL proto-oncogene 1, non-receptor tyrosine kinase
- Target synonymsABL, BCR-ABL, CHDSKM, JTK7, bcr/abl, c-ABL, c-ABL1, p150, v-abl, tyrosine-protein kinase ABL1, ABL protooncogene 1 nonreceptor tyrosine kinase, Abelson tyrosine-protein kinase 1, BCR-ABL1 p190, BCR/ABL e8a2 fusion, BCR/ABL1 e1a2 fusion protein, BCR/ABL1 fusion, BCR/ABL1 fusion protein e3a1, BCR::ABL1 fusion protein, bcr/c-abl oncogene protein, c-abl oncogene 1, receptor tyrosine kinase, chimeric BCR::ABL1 protein, proto-oncogene c-Abl, proto-oncogene tyrosine-protein kinase ABL1, v-abl Abelson murine leukemia viral oncogene homolog 1
- HostRabbit
- IsotypeIgG
- Scientific DescriptionThis gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5 end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. [provided by RefSeq, Aug 2014]
- ReactivityHuman, Mouse, Rat
- Storage Instruction-20°C
- UNSPSC12352203





